

Presents

"Preclinical evidence in support of 5-HT1B receptor agonist treatment of cocaine use disorders"



By

Dr. Janet Neisewander, Professor, School of Life Sciences, Arizona State University

Host: Dr. Art Riegel

Abstract: Initial investigation of the effects of 5-HT1B receptor agonist effects on cocaine selfadministration in rats suggested that these drugs enhance the reinforcing value of cocaine and would be counter-indicated for treatment of cocaine use disorders. However, our research has shown that there is a flip in 5-HT1B receptor agonist effects after a period of forced abstinence in male rats such that these drugs decrease cocaine self-administration and cocaine-seeking behavior. The implications of this line of research for repurposing of 5-HT1B receptor agonists for treatment of cocaine use disorders will be discussed.

> Wednesday, February 9, 2022 11:00 am – Noon - AHSC 8403 Or by Zoom: <u>https://arizona.zoom.us/j/84524481802</u> Meeting ID 845 2448 1802